- Home
- ECOR vs PLUR Comparison
ECOR vs PLUR Comparison
Compare ECOR & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- PLUR
- Stock Information
- Founded
- ECOR 2005
- PLUR 2001
- Country
- ECOR United States
- PLUR Israel
- Employees
- ECOR N/A
- PLUR N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECOR Health Care
- PLUR Health Care
- Exchange
- ECOR Nasdaq
- PLUR Nasdaq
- Market Cap
- ECOR 39.6M
- PLUR 36.9M
- IPO Year
- ECOR 2018
- PLUR N/A
- Fundamental
- Price
- ECOR $4.97
- PLUR $3.80
- Analyst Decision
- ECOR Strong Buy
- PLUR Strong Buy
- Analyst Count
- ECOR 2
- PLUR 1
- Target Price
- ECOR $25.50
- PLUR $12.00
- AVG Volume (30 Days)
- ECOR 78.5K
- PLUR 53.4K
- Earning Date
- ECOR 11-05-2025
- PLUR 11-12-2025
- Dividend Yield
- ECOR N/A
- PLUR N/A
- EPS Growth
- ECOR N/A
- PLUR N/A
- EPS
- ECOR N/A
- PLUR N/A
- Revenue
- ECOR $29,835,000.00
- PLUR $1,326,000.00
- Revenue This Year
- ECOR $24.55
- PLUR $97.38
- Revenue Next Year
- ECOR $41.13
- PLUR $293.97
- P/E Ratio
- ECOR N/A
- PLUR N/A
- Revenue Growth
- ECOR 27.90
- PLUR 121.74
- 52 Week Low
- ECOR $4.16
- PLUR $3.22
- 52 Week High
- ECOR $19.49
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- ECOR 44.55
- PLUR 48.43
- Support Level
- ECOR $4.53
- PLUR $3.60
- Resistance Level
- ECOR $4.98
- PLUR $4.12
- Average True Range (ATR)
- ECOR 0.40
- PLUR 0.38
- MACD
- ECOR -0.09
- PLUR 0.02
- Stochastic Oscillator
- ECOR 17.74
- PLUR 34.27
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.